QGEN logo

QGENQiagen NV

$36.97
$0.78
(2.07%)
Today
Updated: 02:50 PM EDT
EarningsAug 4
Mkt Cap$7.78B
Vol1.77M
News
all
press releases
Qiagen (QGEN) Up 12.1% Since Last Earnings Report: Can It Continue?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
More News
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN PR Newswire NEW YORK, June 4, 2026 NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is...
PR Newswire
News Placeholder
Is QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss?
QIAGEN cuts its 2026 growth outlook after a Q1 miss, but margins, cash flow and a debt-free balance sheet could steady the narrative.
Zacks
News Placeholder
QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of two custom-designed research-use-only (RUO) digital PCR assays to support infectious disease research and surveillance efforts related to the Bundibugyo ebolavirus outbreak. The assays are designed for use...
Business Wire
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN PR Newswire NEW YORK, May 28, 2026 NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is...
PR Newswire
News Placeholder
QIAGEN Business Breakdown and Growth Drivers for 2026
QGEN targets steadier growth through 2027, leaning on new launches, Connect automation and QIAstat-Dx menu expansion amid choppy demand.
Zacks
News Placeholder
QIAGEN Stock Up on the Launch of AI-Powered Workflow Agent Platform
QGEN's new QIA Agent platform uses conversational AI to streamline experiment planning and ordering support.
Zacks
News Placeholder
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the global launch of QIA Agent, an AI-powered digital assistant designed to simplify how researchers plan experiments, identify suitable products, access technical information and manage ordering support through a single...
Business Wire
News Placeholder
Qiagen (QGEN) Securities Fraud Investigation - Levi & Korsinsky
Qiagen (QGEN) Securities Fraud Investigation - Levi & Korsinsky Qiagen (QGEN) Securities Fraud Investigation - Levi & Korsinsky PR Newswire NEW YORK, May 20, 2026 Qiagen shares dropped more than 10% after the company slashed FY 2026 sales-growth guidance from "at least 5% CER" to just 1-2% CER...
PR Newswire
News Placeholder
Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum
ABT's EPD unit posts 9% Q1 sales growth as biosimilars and emerging market demand support its long-term expansion plans.
Zacks
<
1
2
...
>

Advertisement|Remove ads.